Granisetron

Bezeichnung:Granisetron

CAS-Nr109889-09-0

Englisch Name:Granisetron

CBNumberCB2728852

SummenformelC18H24N4O

Molgewicht312.41

MOL-Datei109889-09-0.mol

Granisetron physikalisch-chemischer Eigenschaften

Siedepunkt	532.0±40.0 °C(Predicted)
Dichte	1.33±0.1 g/cm3(Predicted)
storage temp.	Inert atmosphere,Room Temperature
Löslichkeit	25℃: DMSO
Aggregatzustand	Powder
pka	12.34±0.20(Predicted)
Farbe	White to off-white
InChI	InChI=1/C18H24N4O/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23)/t12-,13+,14-/i2D3
InChIKey	MFWNKCLOYSRHCJ-JQHPXDLNNA-N
SMILES	C1(C(=O)N[C@H]2C[C@@]3([H])CCC[C@@]([H])(C2)N3C)C2C=CC=CC=2N(C([2H])([2H])[2H])N=1 \|&1:4,6,11,r\|

Sicherheit

HS Code

2933399090

Gefahreninformationscode (GHS)

Granisetron Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden
Anti-emetic.
Verwenden
Granisetron is a selective 5HT-3 antagonist.
Indications
granisetron (Kytril) is potent antagonists of 5-HT3 receptors,which is found peripherally on vagal nerve terminals and centrally in the CTZ. During chemotherapy that induces vomiting, mucosal enterochromaffin cells in the GI tract release serotonin, which stimulates 5-HT3 receptors.
Definition
ChEBI: A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 1-methyl-1H-indazole-3-carboxylic acid with the primary amino group of (3-endo)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine. A sele tive 5-HT3 receptor antagonist, it is used (generally as the monohydrochloride salt) to manage nausea and vomiting caused by cancer chemotherapy and radiotherapy, and to prevent and treat postoperative nausea and vomiting.
Clinical Use
Prevention or treatment of nausea and vomiting induced by cytotoxic chemotherapy, radiotherapy, or postoperative nausea and vomiting (PONV)
Nebenwirkungen
This causes vagal afferent discharge, inducing vomiting. In binding to 5-HT3 receptors, granisetron blocks serotonin stimulation, hence vomiting, after emetogenic stimuli such as cisplatin. Headache is the most frequently reported adverse effect of these medications.
Arzneimittelwechselwirkung
Potentially hazardous interactions with other drugs
Cytotoxics: possible increased risk of ventricular arrhythmias with panobinostat.
Stoffwechsel
Granisetron is metabolised primarily in the liver by oxidation followed by conjugation. The major compounds are 7-OH-granisetron and its sulphate and glycuronide conjugates. Although antiemetic properties have been observed for 7-OH-granisetron and indazoline N-desmethyl granisetron, it is unlikely that these contribute significantly to the pharmacological activity of granisetron in man. Clearance is predominantly by hepatic metabolism. Urinary excretion of unchanged granisetron averages 12% of dose whilst that of metabolites amounts to about 47% of dose. The remainder is excreted in faeces as metabolites.
Lager
+4°C (desiccate)

Granisetron Upstream-Materialien And Downstream Produkte

Granisetron Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

109889-09-0, Granisetron Verwandte Suche:

Send Inquriy